Benedetto Vitiello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benedetto Vitiello has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anne M. Skrobala
New York State Psychiatric Institute, Columbia University, New York, New York
1 shared publicationCharles Cunningham
McMaster University, Hamilton, Ontario, Canada
1 shared publicationHoward B. Abikoff
Child Study Center, New York University School of Medicine, New York, New York
1 shared publicationJames J. McGough
University of California Los Angeles, Los Angeles, California
1 shared publicationJames M. Swanson
University of California Irvine, Irvine, California
1 shared publicationJames T. McCracken
University of California Los Angeles, Los Angeles, California
1 shared publication
Latest Publications
- 1 October 2007
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 17 (5) , 593-603
Effectiveness of Methylphenidate in the 10-Month Continuation Phase of the Preschoolers with ADHD Treatment Study (PATS)
Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index–Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p < 0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.
- 1 October 2007
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 17 (5) , 593-603
Effectiveness of Methylphenidate in the 10-Month Continuation Phase of the Preschoolers with ADHD Treatment Study (PATS)
Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index–Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p < 0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.